Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 6/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | ACACB | O00763 | 4/20 | 0.35 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | NAMPT | P43490 | 1/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28006794 | 0.80 | NOTUM (0.51) | MAPTALDH1A1POLBCYP2C9CYP2C19 | |
| SCHEMBL578192 | 0.80 | MAPT (0.41) | MAPTALDH1A1POLBCYP2C9CYP2C19 | |
| SCHEMBL28006179 | 0.77 | GFER (0.55) | MAPTALDH1A1POLBCYP2C9CYP2C19 | |
| SCHEMBL578125 | 0.77 | ALDH1A1 (0.46) | MAPTALDH1A1POLBCYP2C9CYP2C19 | |
| SCHEMBL27950762 | 0.76 | MAPT (0.70) | MAPTALDH1A1POLBCYP2C9CYP2C19 | |
| SCHEMBL7401896 | 0.75 | HRH3 (0.62) | MAPTALDH1A1CYP2C9HRH3ACACB | |
| SCHEMBL19859008 | 0.74 | ALDH1A1 (0.57) | MAPTALDH1A1POLBCYP2C9CYP2C19 | |
| SCHEMBL28001502 | 0.74 | KDM4E (0.50) | MAPTALDH1A1POLBCYP2C9CYP2C19 | |
| Hydrochloric Acid SCHEMBL6207497 | 0.73 | HRH3 (0.61) | MAPTALDH1A1CYP2C9HRH3ACACB | |
| Hydrochloric Acid SCHEMBL8632011 | 0.72 | HRH3 (0.60) | MAPTALDH1A1CYP2C9HRH3ACACB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9139563-B2 | Kinase inhibitors and method of treating cancer | UNIVERSITY HEALTH NETWORK (CA) | 2015-09-22 | — | — | US | disclosed |
| US-20140045838-A1 | KINASE INHIBITORS AND METHOD OF TREATING CANCER | UNIV HEALTH NETWORK (CA) | 2014-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140045838-A1 | KINASE INHIBITORS AND METHOD OF TREATING CANCER | MAP3K6, MAP3K5, MAP3K19 | MAPT 2002/4885ALDH1A1 2389/4885POLB 2642/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.